NASDAQ : SNDX
Syndax Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 14.15 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.26B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.22B |
| Enterprise Value | 1.25B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 89.30M |
| Shares Outstanding | 89.30M |
| Shares Change (YoY) | +1.95% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 113.96% |
| Float | 80.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.83 |
| Forward PS | n/a |
| PB Ratio | 80.60 |
| P/TBV Ratio | 80.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.77 |
| Quick Ratio | 6.29 |
| Debt / Equity | 39.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.58 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -255.93% |
| Return on Assets (ROA) | -18.67% |
| Return on Invested Capital (ROIC) | -21.92% |
| Return on Capital Employed (ROCE) | -32.15% |
| Weighted Average Cost of Capital (WACC) | 6.39% |
| Revenue Per Employee | $846,480 |
| Profits Per Employee | -$740,822 |
| Employee Count | 298 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 8.76 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +3.25% |
| 50-Day Moving Average | 17.18 |
| 200-Day Moving Average | 20.23 |
| Relative Strength Index (RSI) | 35.75 |
| Average Volume (20 Days) | 2,764,937 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.00M |
| Short Previous Month | 18.23M |
| Short % of Shares Out | 20.16% |
| Short % of Float | 22.37% |
| Short Ratio (days to cover) | 8.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 252.25M |
| Gross Profit | -20.20M |
| Operating Income | -194.17M |
| Pretax Income | -220.77M |
| Net Income | -220.77M |
| EBITDA | -194.16M |
| EBIT | -194.17M |
| Loss Per Share | -$2.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 554.27M |
| Total Debt | 589.38M |
| Net Cash | -35.12M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | 15.10M |
| Book Value Per Share | 0.17 |
| Working Capital | 575.36M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -220.64M |
| Capital Expenditures | -227,000 |
| Depreciation & Amortization | 11,000 |
| Net Borrowing | 243.85M |
| Free Cash Flow | -220.87M |
| FCF Per Share | -$2.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | -8.01% |
| Operating Margin | -76.98% |
| Pretax Margin | -87.52% |
| Profit Margin | -87.52% |
| EBITDA Margin | -76.97% |
| EBIT Margin | -76.98% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.95% |
| Shareholder Yield | n/a |
| Earnings Yield | -18.42% |
| FCF Yield | -18.12% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.27 |
| Price Target Difference | 173.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 54.70% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.37 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |